Argenx agrees to acquire Unnatural Products for up to $1.15 billion

What Argenx is buying and why it matters

Argenx reached a deal to acquire U.S. biotech Unnatural Products in a transaction that could total $1.15 billion if milestones are met. The Belgian-Dutch drugmaker will pay $550 million now, with as much as $595 million to follow if development and regulatory goals are achieved.

Unnatural Products brings a capability in oral peptides, which Argenx says fits neatly alongside its antibody engineering. Barclays analysts said the technology could let Argenx develop some current experimental drugs and future candidates as pills rather than injectables, calling the deal "a sensible strategic transaction." The two companies have worked together before, and Argenx already owns a minority stake in the closely held target.

The strategy behind the spend

Argenx is pushing to widen its immunology reach after leaning heavily on Vyvgart, its blockbuster medicine. In July, the company struck a deal to acquire Forte Biosciences for about $2.2 billion, bringing in a potential therapy for vitiligo and celiac disease with the possibility to span multiple autoimmune conditions.

Market reaction and what it means for your portfolio

The stock reaction was positive: in Brussels, Argenx climbed as much as 4.1% during early trading and is up about 18% year to date. For investors, this reads as a push to diversify the pipeline and add an oral option to some programs without abandoning the antibody core.

Smart investors explore new tools to gain a clearer perspective on opportunities. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.

The bottom line: the upfront cash secures the peptide know-how, milestone payments stage the risk, and the return hinges on how effectively Argenx translates that science into later stage assets.

Learning how thoughtful technology can sharpen investment decisions is time well spent. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.